News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neurizon Therapeutics.
RELATED STOCKHEAD STORIES
News
Rise & Shine: What you need to know before the ASX opens
Health & Biotech
Dr Boreham’s Crucible: PharmAust wants a piece of the +$US10.2b pet drug market
Health & Biotech
Check-up: Doggy cancer biotech PharmAust leads the pack
Health & Biotech
Biotech: Paradigm might be able to fix your bung Ross River virus joints with an injection
A host of ASX small caps just got a boost from positive news out of the lab
The Pot Seat: Zelda’s Richard Hopkins says registering pot drugs is a luxury
News
Lunchtime ASX small cap wrap: Who’s getting taken down today?
Health & Biotech
Really good boys are experts at taking PharmAust’s cancer drug
Health & Biotech
‘Mice are a failed experiment’: Why you shouldn’t get revved up about pre-clinical trials
Health & Biotech
PharmAust says its cancer drug for fussy dogs is way tastier now
Health & Biotech
PharmAust’s anti-cancer drug passed an important test on the way to human trials
Health & Biotech
PharmAust wins all-important licence to start testing its doggy cancer pill
Health & Biotech
PharmAust pinches key exec from animal health company Elanco
Health & Biotech
